Login to Your Account

Hutchison's fruquintinib advances to late-stage colorectal cancer trial

By Alfred Romann
Staff Writer

Tuesday, March 31, 2015
HONG KONG – Calling success in the first proof-of-concept trial for its cancer drug, fruquintinib, Hong Kong-based Hutchison Medipharma said the drug achieved primary efficacy endpoints.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription